Misplaced Pages

Golidocitinib: Difference between revisions

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Browse history interactively← Previous editContent deleted Content addedVisualWikitext
Revision as of 19:59, 23 December 2024 editCitation bot (talk | contribs)Bots5,420,661 edits Add: page, display-authors, pmid, pages, issue, volume, journal, date, title, authors 1-30. | Use this bot. Report bugs. | Suggested by Innerstream | #UCB_webform← Previous edit Latest revision as of 01:30, 26 December 2024 edit undoGraeme Bartlett (talk | contribs)Administrators249,716 edits more ids 
(5 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{cs1 config|name-list-style=vanc|display-authors=6}}
{{Infobox drug {{Infobox drug
| drug_name = | drug_name =
Line 4: Line 5:
| type = <!-- empty --> | type = <!-- empty -->
| image = Golidocitinib.svg | image = Golidocitinib.svg
| width =
| alt = | alt =
| caption = | caption =
| image2 =
| width2 =
| alt2 =
| caption2 =
| imageL =
| widthL =
| altL =
| imageR =
| widthR =
| altR =
| captionLR =

<!-- Clinical data --> <!-- Clinical data -->
| pronounce = | pronounce =
| tradename = 高瑞哲 | tradename = 高瑞哲 (Gao Ruizhe)
| Drugs.com = | Drugs.com =
| MedlinePlus = | MedlinePlus =
| licence_CA =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| licence_EU =
| DailyMedID =
| licence_US =
| pregnancy_AU =
| pregnancy_AU_comment = | pregnancy_AU_comment =
| pregnancy_category= | pregnancy_category=
| dependency_liability =
| addiction_liability =
| routes_of_administration = | routes_of_administration =
| class =
| ATCvet = | ATCvet =
| ATC_prefix = <!-- 'none' if uncategorised --> | ATC_prefix = <!-- 'none' if uncategorised -->
| ATC_suffix = | ATC_suffix =
| ATC_supplemental =

<!-- Legal status -->
<!-- Legal status --> <!-- Legal status -->
| legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled --> | legal_AU = <!-- S2, S3, S4, S5, S6, S7, S8, S9 or Unscheduled -->
Line 38: Line 62:
| legal_UN_comment = | legal_UN_comment =
| legal_status = Rx in China | legal_status = Rx in China

<!-- Pharmacokinetic data --> <!-- Pharmacokinetic data -->
| bioavailability = | bioavailability =
Line 47: Line 72:
| duration_of_action= | duration_of_action=
| excretion = | excretion =

<!-- Identifiers --> <!-- Identifiers -->
| synonyms = AZD-4205, AZD4205, JAK1-IN-3 | CAS_number = 2091134-68-6
| CAS_supplemental =
| CAS_number = 2091134-68-6
| PubChem = 126715380 | PubChem = 126715380
| PubChemSubstance =
| IUPHAR_ligand =
| DrugBank = DB18057
| ChemSpiderID = 71117616
| UNII = 3BY9Z3M34G | UNII = 3BY9Z3M34G
| DrugBank = | KEGG = D12502
| ChEBI =
| ChEMBL = 4577523
| NIAID_ChemDB =
| PDB_ligand =
| synonyms = AZD-4205, AZD4205, JAK1-IN-3

<!-- Chemical and physical data --> <!-- Chemical and physical data -->
| IUPAC_name = (2''R'')-''N''-pyrimidin-4-yl]-1''H''-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide | IUPAC_name = <nowiki>(2R)-N-pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide</nowiki>
| C = 25 | H = 31 | N = 9 | O = 2 | C=25 | H=31 | N=9 | O=2
| molecular_weight =
| SMILES = C(C(=O)NC1=CC=CC2=C1NC=C2C3=NC(=NC=C3)NC4=CN(N=C4OC)C)N5CCN(CC5)C
| Jmol =
| StdInChI = InChI=1S/C25H31N9O2/c1-16(34-12-10-32(2)11-13-34)23(35)28-20-7-5-6-17-18(14-27-22(17)20)19-8-9-26-25(29-19)30-21-15-33(3)31-24(21)36-4/h5-9,14-16,27H,10-13H2,1-4H3,(H,28,35)(H,26,29,30)/t16-/m1/s1
| StdInChI_comment =
| StdInChIKey = CVCVOSPZEVINRM-MRXNPFEDSA-N
| density =
| density_notes =
| melting_point =
| melting_high =
| melting_notes =
| boiling_point =
| boiling_notes =
| solubility =
| sol_units =
| specific_rotation =
}} }}


'''Golidocitinib''' is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory ].<ref>{{Cite journal | doi = 10.1007/s40265-024-02089-2 | title = Golidocitinib: First Approval | date = 2024 | last1 = Keam | first1 = Susan J. | journal = Drugs | volume = 84 | issue = 10 | pages = 1319–1324 | pmid = 39298087 }}</ref> '''Golidocitinib''' is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory ].<ref>{{cite journal | vauthors = Keam SJ | title = Golidocitinib: First Approval | journal = Drugs | volume = 84 | issue = 10 | pages = 1319–1324 | date = October 2024 | pmid = 39298087 | doi = 10.1007/s40265-024-02089-2 }}</ref>

Golidocitinib is classified as a ].<ref>{{Cite journal | doi = 10.1016/S1470-2045(23)00589-2 | title = Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): A single-arm, multinational, phase 2 study | date = 2024 | last1 = Song | first1 = Yuqin | last2 = Malpica | first2 = Luis | last3 = Cai | first3 = Qingqing | last4 = Zhao | first4 = Weili | last5 = Zhou | first5 = Keshu | last6 = Wu | first6 = Jianqiu | last7 = Zhang | first7 = Huilai | last8 = Mehta-Shah | first8 = Neha | last9 = Ding | first9 = Kaiyang | last10 = Liu | first10 = Yao | last11 = Li | first11 = Zengjun | last12 = Zhang | first12 = Liling | last13 = Zheng | first13 = Meifang | last14 = Jin | first14 = Jie | last15 = Yang | first15 = Haiyan | last16 = Shuang | first16 = Yuerong | last17 = Yoon | first17 = Dok Hyun | last18 = Gao | first18 = Sujun | last19 = Li | first19 = Wenyu | last20 = Zhai | first20 = Zhimin | last21 = Zou | first21 = Liqun | last22 = Xi | first22 = Yaming | last23 = Koh | first23 = Youngil | last24 = Li | first24 = Fei | last25 = Prince | first25 = Miles | last26 = Zhou | first26 = Hui | last27 = Lin | first27 = Lie | last28 = Liu | first28 = Hui | last29 = Allen | first29 = Pamela | last30 = Roncolato | first30 = Fernando | journal = The Lancet Oncology | volume = 25 | issue = 1 | pages = 117–125 | pmid = 38092009 | display-authors = 1 }}</ref><ref>{{Cite journal | doi = 10.1182/blood-2024-211891 | title = Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26) | date = 2024 | last1 = Jin | first1 = Jie | last2 = Zhang | first2 = Liling | last3 = Zou | first3 = Liqun | last4 = Li | first4 = Zengjun | last5 = Wu | first5 = Huijing | last6 = Zhou | first6 = Keshu | last7 = Qiu | first7 = Lihua | last8 = Su | first8 = Liping | last9 = Ding | first9 = Kaiyang | last10 = Zhou | first10 = Hui | last11 = Yu | first11 = Li | last12 = Li | first12 = Fei | last13 = Xiao | first13 = Qing | last14 = Li | first14 = Wenyu | last15 = Lin | first15 = Lie | last16 = Wang | first16 = Erhua | last17 = Chen | first17 = Lijia | last18 = Cai | first18 = Qingqing | journal = Blood | volume = 144 | page = 6368 }}</ref>


Golidocitinib is classified as a ].<ref>{{cite journal | vauthors = Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, Zhang H, Mehta-Shah N, Ding K, Liu Y, Li Z, Zhang L, Zheng M, Jin J, Yang H, Shuang Y, Yoon DH, Gao S, Li W, Zhai Z, Zou L, Xi Y, Koh Y, Li F, Prince M, Zhou H, Lin L, Liu H, Allen P, Roncolato F, Yang Z, Kim WS, Zhu J | title = Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study | journal = The Lancet. Oncology | volume = 25 | issue = 1 | pages = 117–125 | date = January 2024 | pmid = 38092009 | doi = 10.1016/S1470-2045(23)00589-2 }}</ref><ref>{{Cite journal | doi = 10.1182/blood-2024-211891 | title = Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26) | date = 2024 | vauthors = Jin J, Zhang L, Zou L, Li Z, Wu H, Zhou K, Qiu L, Su L, Ding K, Zhou H, Yu L, Li F, Xiao Q, Li W, Lin L, Wang E, Chen L, Cai Q | journal = Blood | volume = 144 | page = 6368 }}</ref>


==References== == References ==
{{reflist}} {{reflist}}


Line 71: Line 122:
] ]
] ]
]
]


{{antineoplastic-drug-stub}} {{antineoplastic-drug-stub}}

Latest revision as of 01:30, 26 December 2024

Pharmaceutical compound
Golidocitinib
Clinical data
Trade names高瑞哲 (Gao Ruizhe)
Other namesAZD-4205, AZD4205, JAK1-IN-3
Legal status
Legal status
  • Rx in China
Identifiers
IUPAC name
  • (2R)-N-pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC25H31N9O2
Molar mass489.584 g·mol
3D model (JSmol)
SMILES
  • C(C(=O)NC1=CC=CC2=C1NC=C2C3=NC(=NC=C3)NC4=CN(N=C4OC)C)N5CCN(CC5)C
InChI
  • InChI=InChI=1S/C25H31N9O2/c1-16(34-12-10-32(2)11-13-34)23(35)28-20-7-5-6-17-18(14-27-22(17)20)19-8-9-26-25(29-19)30-21-15-33(3)31-24(21)36-4/h5-9,14-16,27H,10-13H2,1-4H3,(H,28,35)(H,26,29,30)/t16-/m1/s1
  • Key:CVCVOSPZEVINRM-MRXNPFEDSA-N

Golidocitinib is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.

Golidocitinib is classified as a Janus kinase inhibitor.

References

  1. Keam SJ (October 2024). "Golidocitinib: First Approval". Drugs. 84 (10): 1319–1324. doi:10.1007/s40265-024-02089-2. PMID 39298087.
  2. Song Y, Malpica L, Cai Q, Zhao W, Zhou K, Wu J, et al. (January 2024). "Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study". The Lancet. Oncology. 25 (1): 117–125. doi:10.1016/S1470-2045(23)00589-2. PMID 38092009.
  3. Jin J, Zhang L, Zou L, Li Z, Wu H, Zhou K, et al. (2024). "Maintenance Therapy of Golidocitinib, a JAK1 Selective Inhibitor, in Patients with Peripheral T Cell Lymphomas after First-Line Systemic Therapy: Updates of the Phase 2 Study (JACKPOT26)". Blood. 144: 6368. doi:10.1182/blood-2024-211891.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: